Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ANNX vs STOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STOK Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–1 Matrix Metrics)

STOK Overall Winner 6-Pillar Tally: ANNX 0 – 5 STOK (1 Tie) Matrix Metrics: ANNX 1 – 6 STOK

As of Nov 16, 2026, Stoke Therapeutics, Inc. (STOK) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.58 (N/M Forward P/E, 0.0% operating margin), whereas STOK carries 56.7/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin).

  • Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 50.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANNX vs STOK
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.58
-8.55% 1D
Market Cap $757.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.68β · 62% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 42.0 Fund 54.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.3%), weak momentum, RSI 38
RSI-14: 37.9 · SMA20: $3.98 · SMA50: $4.00
STOK NASDAQ Head-to-Head Winner
Stoke Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$26.54
-0.52% 1D
Market Cap $1.7B
TTM Revenue $28M
Forward P/E N/M
Beta / 30D Vol 0.99β · 47% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.5 · SMA20: $26.46 · SMA50: $26.39

6-Pillar Scorecard Institutional Category Breakdown (ANNX 0 – 5 STOK)

Columns: Metric · ANNX · STOK
1. Valuation Multiples STOK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 57.0x
2. Growth & Scale STOK
Revenue Growth (YoY) +0.0% +5.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $28M
Market Cap $757.3M $1.7B
3. Profitability & Quality STOK
Gross Margin N/A 100.0%
Operating Margin 0.0% -913.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -130.8% -73.6%
4. Balance Sheet & Cash Flow STOK
Cash Generation (TTM) -$190M -$216M
Cash Flow Margin N/A N/A
Net Cash / Leverage $29M Net Cash $106M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STOK
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 209.2% (40th %ile) 63.5% (8th %ile)
Put/Call OI Skew 0.75x (Call-Skewed) 3.80x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANNX (1) vs STOK (6)
Institutional Metric ANNX STOK Criterion Row Edge
Market Capitalization
Scale
$757.3M $1.7B Larger Scale STOK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +5.9% Higher Growth STOK
Operating Margin (TTM)
Profitability
0.0% -913.2% Higher Margin ANNX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-130.8% -73.6% Higher ROE STOK
52-Week Range Position
Momentum
22% ($3–$7) 25% ($22–$40) Stronger Trend STOK
Beta / 30D Volatility
Risk Regime
1.68β · 62% Vol 0.99β · 47% Vol Lower Realized Risk STOK
Unified Institutional Score
Composite Signal
44.6 / 100 (HOLD) 56.7 / 100 (HOLD) Higher Composite STOK
Trailing 12M Revenue (USD)
Operating Scale
N/A $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 57.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$190M ($29M Net Cash) -$216M ($106M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STOK +4.68 pp
ANNX: +5.13% · STOK: +9.81%
3M Horizon STOK +14.68 pp
ANNX: -32.1% · STOK: -17.42%
6M Horizon STOK +19.14 pp
ANNX: -27.72% · STOK: -8.58%
1Y Horizon ANNX +31.97 pp
ANNX: +33.77% · STOK: +1.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs STOK. Trailing 12-month operating profitability (ANNX 0.0% vs STOK -913.2%) and valuation multiples (ANNX N/M vs STOK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M
STOK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin100.0%
Op. Margin-913.2%
ROE / Fwd P/E-73.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANNX BREAKDOWN
87d in phase · OBV DISTRIBUTION
Current IV 209.2%
IV Percentile 40th %ile
Put/Call OI Skew 0.75x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STOK SURGE
5d in phase · OBV ACCUMULATION
Current IV 63.5%
IV Percentile 8th %ile
Put/Call OI Skew 3.80x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact STOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $757.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STOK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -913.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANNX vs STOK Key Questions & Quantitative Answers

As of Nov 16, 2026, Stoke Therapeutics, Inc. (STOK) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANNX carries a Unified Composite Score of 44.6/100 (HOLD) at $3.58 (N/M Forward P/E, 0.0% operating margin), whereas STOK carries 56.7/100 (HOLD) at $26.54 (N/M Forward P/E, -913.2% operating margin). Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.9); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 50.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STOK leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with STOK at +5.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (100.0% gross margin, -913.2% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus $28M for STOK. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STOK.

STOK screens cheaper on headline valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas STOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 57.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus STOK (-73.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ANNX carries 209.2% implied volatility (40th %ile, Balanced (25th–60th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 62% Vol realized risk). By comparison, STOK carries 63.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 3.80x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.99β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.